Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Biotech announced FDA written feedback supporting a potential pivotal Part B expansion of its REO 033 study evaluating pelareorep in second-line RAS-mutant microsatellite stable metastatic colorectal cancer. The FDA feedback aligns with the proposed study design to pursue accelerated approval based on objective response rate and progress…